Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Michael Catelani Buys 5,500 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) CFO Michael Catelani purchased 5,500 shares of the stock in a transaction dated Wednesday, September 30th. The shares were purchased at an average price of $2.84 per share, with a total value of $15,620.00. Following the completion of the transaction, the chief financial officer owned 50,000 shares of the company’s stock, valued at approximately $142,000. This trade represents a 12.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Anixa Biosciences Stock Up 2.8%

Anixa Biosciences stock traded up $0.08 during mid-day trading on Wednesday, reaching $2.93. 178,371 shares of the company’s stock were exchanged, compared to its average volume of 205,258. The company has a fifty day moving average of $3.21 and a 200-day moving average of $2.97. The company has a market cap of $101.86 million, a P/E ratio of -9.16 and a beta of 0.51. Anixa Biosciences Inc has a twelve month low of $2.32 and a twelve month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). Equities research analysts expect that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings raised Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. HC Wainwright reduced their price target on Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, September 22nd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday, June 30th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.00.

Hedge Funds Weigh In On Anixa Biosciences

Several large investors have recently added to or reduced their stakes in ANIX. Sanctuary Advisors LLC bought a new position in Anixa Biosciences during the 2nd quarter worth $29,000. Northwestern Mutual Wealth Management Co. bought a new position in Anixa Biosciences during the 2nd quarter valued at $29,000. Integrated Wealth Concepts LLC bought a new stake in Anixa Biosciences in the second quarter worth about $30,000. Simplicity Wealth LLC bought a new position in shares of Anixa Biosciences during the 2nd quarter valued at about $34,000. Finally, NewEdge Wealth LLC bought a new stake in shares of Anixa Biosciences in the 2nd quarter worth approximately $35,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.